TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02835040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New model of service delivery
Description: Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current practice
Description: Interventions as determined by the treating General Medical team consistent with current usual practice.
Study: NCT03034239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: + insect protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: Resistance exercise
Study: NCT00852371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine
Description: 25 mg/kg po once on day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine + sulfadoxine-pyrimethamine
Description: Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Description: 2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
Study: NCT03450330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205
Description: Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
Study: NCT03601234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic and endoscopic cooperative surgery
Description: compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: the traditional surgery
Study: NCT02139059

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: initial urinary drainage
Description: initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: direct ureteroscopy
Description: direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
Study: NCT02470715

Intervention type: GENETIC
Intervention: Molecular profile
Description: Patients and their treating physician will obtain the patient's genetic risk assessment
Study: NCT05984251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT02589392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil® Restoraderm® body wash
Study: NCT05984251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT03265223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% ropivacaine
Description: Intraperitoneal instillation versus intraincisional infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% ropivacaine
Description: Intraperitoneal instillation versus intraincisional infiltration
Study: NCT03952390

Intervention type: OTHER
Intervention: control

Intervention type: OTHER
Intervention: sepsis
Study: NCT02160132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone(intravenously in the 1st-2nd-3rd month )
Description: Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone(intravenously in the 1st-3rd-5th month)
Description: Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
Study: NCT04486300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic reduction and Laparotomy
Description: Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
Study: NCT01814280

Intervention type: OTHER
Group type: OTHER
Intervention: Medication review
Description: Medication review performed by either a clinical pharmacist or a clinical pharmacologist
Study: NCT04769999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task
Description: A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
Study: NCT02384642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COMPASS
Description: COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPASS plus parenting
Description: The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
Study: NCT03837522

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Procurement Biopsy: Frozen section
Description: Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Procurement Biopsy: Permanent section
Description: Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
Study: NCT01967381

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine (Desoxyn®)
Description: The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
Study: NCT04360447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reformer Pilates
Description: Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
Study: NCT02898012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage \> grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
Study: NCT00902629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early surgery
Description: Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
Study: NCT01306760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine used as the anaesthetic during ECT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The standard anaesthetic used for ECT.
Study: NCT01776125

Intervention type: OTHER
Intervention: Cheek swab
Description: Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.

Intervention type: OTHER
Intervention: Cheek swab
Description: Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
Study: NCT03506503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat grafting
Description: hair loss area will be treated by processed autologous Nanofat grafting
Study: NCT04545957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Simulator
Description: Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Simulator
Description: Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Simulator
Description: Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
Study: NCT02190734

Intervention type: OTHER
Group type: OTHER
Intervention: Sitting in wheel chair
Description: Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: Gait training on treadmill
Description: Walking on a treadmill with or without body weight support during 30 minute treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Gait training overground
Description: Walking overground with or without body weight support during 30 minute treatment
Study: NCT01967381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine (Desoxyn®)
Description: The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
Study: NCT01478958

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SFA diet
Description: Volunteers are following a high saturated fat diet for a 4-month period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MUFA diet
Description: Volunteers are following a high monounsaturated fat diet for a 4-month period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-6 PUFA diet
Description: Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
Study: NCT02909153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
Study: NCT03252782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst Appliance
Description: Acrylic Splint Herbst Appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distal Jet Appliance
Description: Anterior Median Palate Implant Borne Distal Jet Appliance
Study: NCT02197260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days
Description: Systemic antibiotics after sub gingival mechanical debridement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days
Description: Systemic antibiotics after sub gingival mechanical debridement
Study: NCT03956862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001
Description: film-coated oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablet
Study: NCT03137108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical spinal cord stimulation
Description: Study intervention consists of the application of tSCS at three different frequencies (15 Hz, 30 Hz, 50 Hz) using the CE certified electrostimulator RehaMove 3. Stimulation will only be applied by an investigator during the two testing sessions. During the overground walking, the participants will be secured and assisted with the cable-driven body-weight support system FLOAT.
Study: NCT02203058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed-lips breathing
Description: Expiration with pursed-lips during functional capacity tests.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No pursed-lips breathing
Description: To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
Study: NCT00469417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix® cream

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand held liquid nitrogen spray cryotherapy
Study: NCT00705536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study: NCT02957097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Medication used for management of neuropathic pain conditions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
Study: NCT03656913

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extremely low dose CT
Description: Patients undergoing clinically indicated CT will also receive the extremely low dose CT
Study: NCT01447615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridges
Description: Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridges PLUS
Description: Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
Study: NCT01824537

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine, Gardasil 9
Description: Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Provided by Sanofi Pasteur.
Study: NCT01967381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine (Desoxyn®)
Description: The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine (Desoxyn®)
Description: The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
Study: NCT04207203

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: sodium zirconium cyclosilicate and healthy diet
Description: During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.